Keybanc analyst Kenneth Zener upgrades KB Home (NYSE:KBH) from Underweight to Sector Weight.
Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications
Indaptus Therapeutics Inc (NASDAQ: INDP) announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company's Decoy anti-tumor platform.
